Free Deal Calculator

Calculate Monoclonal Antibody Deal Values Instantly

Get precise licensing valuations based on $2.5B+ in real market transactions and current deal benchmarks.

Market-Validated Pricing

Access real-time benchmarks from $700M-$2.5B total deal values. Our algorithm factors in the mature mAb market dynamics and current 3% premium rates.

Instant Deal Scenarios

Generate comprehensive licensing terms in seconds, not weeks. Compare Phase 2 upfront payments ($60M-$250M) across different deal structures immediately.

Investor-Grade Accuracy

Built on transaction data from 200+ actual licensing deals. The same valuation methodology used by top-tier BD teams and investment banks.

$2.5B+

Deal Values Analyzed

200+

mAb Transactions Tracked

15 min

Average Time Saved

94%

Accuracy vs. Final Terms

How It Works

Input Asset Details

Enter your monoclonal antibody's development stage, indication, and key differentiation factors into our structured form.

AI Analyzes Market Data

Our algorithm benchmarks your asset against comparable deals, factoring in mature market dynamics and current premium rates.

Download Deal Scenarios

Receive detailed valuation ranges, milestone structures, and royalty recommendations formatted for investor presentations.

Frequently Asked Questions

How accurate are monoclonal antibody valuations in today's market?

Our calculator reflects the current mature mAb market with 94% accuracy vs. final deal terms. We account for commoditization trends while recognizing the 3% premium that differentiated naked mAbs still command.

What's typical for Phase 2 monoclonal antibody upfront payments?

Current Phase 2 upfront payments range from $60M-$250M depending on indication, competitive landscape, and differentiation. Oncology indications typically command the higher end of this range.

How do naked mAbs compare to ADCs in licensing deals?

Naked monoclonal antibodies face pricing pressure from biosimilars and competition, but proven assets with strong IP and differentiation still achieve significant premiums, particularly in specialized indications.

Should I wait for Phase 3 data before licensing my mAb?

Phase 2 licensing maximizes risk-adjusted returns for most naked mAbs. Our calculator helps you compare Phase 2 vs. Phase 3 deal scenarios to optimize your licensing strategy timing.

Ready to Calculate Your Deal Terms?

Get instant benchmarks based on real market data from recent biotech licensing deals.

Start Calculating